Human Trials Begin for Rejuvenation Therapy Targeting Eye Disease and Glaucoma

10 articles · Updated · The New York Times · Apr 27

The first safety trials started in March 2026, aiming to reverse eye disease and cure glaucoma using cellular rejuvenation techniques.
Scientists hope this therapy could restore vision by reversing cellular aging in the eyes, marking a major step in longevity research.
This development follows decades of breakthroughs in animal studies and is backed by significant investment from leading biotech entrepreneurs seeking to extend healthy human lifespan.

Human trials for cellular rejuvenation have begun. What are the biggest unforeseen risks?

Science suggests a 120-year lifespan limit. Can new therapies truly break this biological ceiling?

Tech billionaires are funding the anti-aging race. What if only the rich live longer?

We all reversed aging as embryos. Why does our body lose this remarkable ability?

The FDA now targets aging as a disease. How does this change the future of medicine?

If aging is curable, will society ever agree on when it is acceptable to die?